January 22, 2017 8:20 PM ET


Company Overview of Five Prime Therapeutics, Inc.

Company Overview

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes in the United States. The company’s product candidates include FPA008, an antibody that inhibits colony stimulating factor-1 receptor and is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor, as well as conducts Phase I clinical trials for the treatment of rheumatoid arthritis. Its product candidates also comprise FPA144, an antibody that inhibits fibroblast grow...

Two Corporate Drive

South San Francisco, CA 94080

United States

Founded in 2001

154 Employees





Key Executives for Five Prime Therapeutics, Inc.

Founder, Chairman, Chief Executive Officer and President
Age: 67
Total Annual Compensation: $525.0K
Chief Operating Officer and Director
Age: 47
Total Annual Compensation: $383.5K
Chief Strategy Officer and Secretary
Age: 45
Total Annual Compensation: $358.5K
Compensation as of Fiscal Year 2015.

Five Prime Therapeutics, Inc. Key Developments

Five Prime Therapeutics, Inc. Provides Earnings Guidance for the Fiscal Year 2017

Five Prime Therapeutics, Inc. expects net cash used in operations for fiscal year 2017 will be less than $120 million.

Five Prime Therapeutics, Inc. and Bristol-Myers Squibb Company Extend Research Term in Collaboration to Discover Novel Immuno-Oncology Therapies

Five Prime Therapeutics, Inc. announced that Bristol-Myers Squibb Company has exercised its option to extend the research term of its discovery collaboration agreement with Five Prime for the discovery, development and commercialization of immuno-oncology therapies directed toward targets in three undisclosed immune checkpoint pathways. The original collaboration agreement was established in March 2014 and focused on two undisclosed immune checkpoint pathways. In January 2016, the companies added a third immune checkpoint pathway to the collaboration. Bristol-Myers Squibb has now elected to extend the research term from its original ending date of March 2017 to March 2018, and will provide additional research funding for the 12-month extension of the research term. Bristol-Myers Squibb will utilize Five Prime's discovery capabilities to advance these three immuno-oncology programs toward the identification of drug candidates for continued research and development. Under the terms of the original agreement, Bristol-Myers Squibb will obtain exclusive, worldwide rights to develop and commercialize products directed toward certain protein targets in the three checkpoint pathways identified by Five Prime prior to and during the collaboration. Bristol-Myers Squibb paid an upfront fee of $20 million to Five Prime and will provide up to $11.6 million in research funding over the course of the entire research term. Five Prime will be eligible to receive up to $300 million in future development (including $5 million upon filing of the first IND application by Bristol-Myers Squibb), regulatory and sales-based milestone payments per collaboration product and tiered mid-single-digit rising to low-double-digit royalty payments on net sales of each product commercialized by Bristol-Myers Squibb.

Five Prime Therapeutics, Inc. Presents at 35th Annual JP Morgan Healthcare Conference, Jan-10-2017 09:30 AM

Five Prime Therapeutics, Inc. Presents at 35th Annual JP Morgan Healthcare Conference, Jan-10-2017 09:30 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, CA 94102, United States. Speakers: Lewis T. Williams, Founder, Chairman, Chief Executive Officer and President.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Five Prime Therapeutics, Inc., please visit www.fiveprime.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.